The present invention relates to systems and methods for storing, transporting, measuring, collecting, and analyzing blood.
Blood is a complex fluid, comprising a watery plasma containing various proteins (principally albumin) and large cells (principally red blood cells). Quantitative collection of blood must deal with a variety of factors specific to blood including: the potential for clotting (especially when exposed to air); the potential for hemolysis (when the fluid is disturbed or agitated excessively); the potential for settling (the tendency of red blood cells to sink when blood is allowed to stand under the influence of gravity, resulting in an inhomogeneous mixture of red cells and plasma in the sample); the potential for surface adhesion (the proteins in blood are generally “sticky” and will adhere to most plastic surfaces, and will resist displacement under typical flow conditions); and the potential for non-laminar flow caused by partial separation on the blood components caused by the geometry of the blood pathway through the vial. As a result of these issues, quantitative measurements of blood that require volumes greater than 0.15 ml generally involve a cumbersome, multi-step process. First blood is collected (e.g. into a vacutainer tube at the bedside) and then it must be transferred quantitatively into a separate container (e.g. using a precision pipette at a laboratory bench). Pipetting of whole blood is quite difficult and potentially inaccurate, because of all the issues including settling, adhesion, hemolysis, etc. Centrifuging whole blood to get access to plasma is feasible, but this adds time and complexity to a quantitative process, and still requires skill in pipetting to ensure accuracy (e.g. to pipette only plasma and no red cells). For all these reasons a solution enabling direct collection of precise amounts of whole blood directly from a patient for the purposes of quantitative measurement is desirable.
Hct is defined as the volume percentage of red blood cells in whole blood. Hct is typically measured in a variety of ways. Automated analyzers performing Complete Blood Count (CBC) testing typically measure the Hct as the product of Mean Cell Volume (MCV) and the Red Blood Cell (RBC) Count, with RBC in units of concentration. These CBC devices are large, complex, expensive, and laboratory-based. The gold standard method for direct determination of Hct uses the percentage of volume method, by which the volume of spun red cells is directly compared to the volume of the original sample. Typical embodiments of this method use capillary tubes which are filled with blood, then spun in a microcentrifuge; the proportion of red cells can be measured by comparing linear distance of the colored portions of the capillary tube. Various Point-of-Care (POC) devices exist which can measure Hct—or Hemoglobin (Hb) concentration, which can be converted to Hct via a numerical factor-but these devices generally lack the precision and accuracy, and/or the extended range of the lab methods. In the present invention, a single tracer is used that marks one component of the whole blood (either the red cells or the plasma), and that tracer is then measured in samples of whole blood and extracted plasma.
Many forms of quantitative vials for fluid collection exist. These are generally designed to collect very small quantities of fluid, which are then measured by some means. The present invention deals with the situation where the vial is designed to be fillable using an ordinary syringe without any special training; and where the volume of fluid to be collected is at least 0.5 ml (i.e. greater than the approximate maximum of 0.15 ml using capillary action). The use of a precise geometry for the vial facilitates applications where measurements of a sample (collected or monitored in the vial) are compared with measurements of a reference standard (contained in an identical vial, or in a vial with a known ratio of volume to the quantitative vial). An example of such an application would be the measurement of an unknown volume using the indicator dilution method, whereby a known amount of tracer is introduced into the unknown volume; the amount of tracer present in a sample collected from the unknown volume can be directly compared to the amount of tracer present in a reference standard created by diluting the same tracer into a known volume, and filling an identical vial with the resulting dilution.
A device is presented for storing, transporting, measuring, and collecting blood, having the properties of being easily filled to a precisely determined volume, and a geometry suitable for the entire device to be efficiently placed in the counting chamber of a detector (such as the counting well of a gamma counter). This device features in a method for determining Hematocrit in a sample of blood, using a tracer which is counted in precise volumes of the blood sample, and in plasma derived from the same sample.
The invention provides a vial of precise volume, comprising an ingress with a standard fitting for accepting fluid and a valve to prevent backflow or outflow of the fluid, and an egress incorporating a membrane which passes air but retains fluid. In one embodiment, the standard fitting is a luer-lock mechanism.
In a one embodiment, the vial is formed from four separate components: an ingress adapter incorporating a luer lock and a valve, a membrane with pressure resistance, defined as water entry pressure or WEP, sufficient to prevent flow of fluid, a lid to which the membrane is affixed, and a vial body which connects the lid to the adapter, defining a precise volume. In one embodiment, the components are assembling using adhesive (such as cyanoacrylate). In a preferred embodiment, the components are assembled using injection molding.
In one embodiment, the vial is designed to be compact (i.e. having a small height relative to the depth of a counting well), such that the entire sample in the vial is deep within the well. This increases the counting efficiency for the sample and minimizes counting geometry effects for inhomogeneities in the sample. In one embodiment, the well is a complete cylindrical cutout, allowing vials to be inserted from one side and removed from the other.
In one embodiment, the membrane is supported by a dense structure, increasing its effective WEP rating. In another embodiment, the membrane is supported by a sparse structure, increasing its effective surface area for passage of air.
In one embodiment, the vial body is formed from transparent material with sufficient clarity to allow visual inspection of the vial by the user, to verify that the vial is completely filled, with no visible air spaces. A partial list of materials that are both injection moldable and have sufficient clarity includes: Acrylic (PMMA), Acrylonitrile butadiene styrene (ABS), Nylon (polyamide, PA), Polycarbonate (PC), Polyethylene (PE), Polyoxymethylene (POM) (Delrin), Polypropylene (PP), Polystyrene (PS), Thermoplastic Elastomer (TPE), and Thermoplastic Polyurethane (TPU). Sufficient clarity also allows for quantitative measurement of light emitted from or absorbed by the liquid in the vial when placed in a suitable detection apparatus.
In one embodiment, the vial incorporates smooth curved transitions between all components to ensure that no air is trapped in the vial while it is filled by eliminating spaces where are bubbles could form and thereby prevent the exact desired volume from being achieved in the vial.
In one embodiment, the vial is fitted with an additional access point, equipped with an adapter for accepting liquid via a luer lock or standard threaded connection and a valve, to provide a means of applying or relieving pressure. Such an adapter with a suitable pressure release valve can ensure that the vial membrane does not experience pressure that exceeds the membrane WEP, thus preventing leakage or failure of the membrane.
In one embodiment, the inner surfaces of the vial are treated, either before or after assembly, with a finish coating that has the property of having low adhesion for blood. A partial list of methods of achieving such coatings include the use of super-hydrophobic polystyrene coatings such as MnO2/PS or ZnO/PS, silica nano-coating, mold temperature hydrophobicity tuning, or zwitterion coating.
In one embodiment, the vial can be shaped to fit the geometry of a detector. For example, a cylindrical vial could fit completely in a cylindrical well such as is typically found in a gamma counter. A conical vial, alternatively, concentrates the sample in the bottom of such cylindrical well, minimizing variations in counting caused by settling effects in the vial by concentrating most of the sample at the bottom of the vial. A spherical or rectangular prism shape for the vial can be shaped to fit a spherical or rectangular prism well. In one embodiment, the detector well has a fold-over design allowing the vial to be partially or completely encased in the detector.
In another preferred embodiment, an injectable tracer and dimensionally identical reference standard and collection vials are included as components of a kit to enable an indicator dilution measurement to be performed. A reference standard vial is prepared by diluting tracer from the same production lot as the injectable tracer) into a known volume (e.g. 1000 ml).
In one embodiment, a separate disposable sleeve is provided, of suitable size and dimensions to accept the vial, with the vial-enclosed sleeve fitting into the detector. The sleeve serves to facilitate handling of the sample vial, and to protect both the user and the detector from possible contamination by the blood contained within the vial, as might occur if the membrane were to fail or be damaged, or the cartridge were otherwise to leak. The sleeve also facilitates agitation of the sample, whereby the sample vial is shaken by hand to counteract any settling that may have occurred in the time between filling the vial and counting it in the detector.
The invention also provides a method for determining Hct where a single quantitative tracer that labels the plasma is introduced into a sample of whole blood. This introduction can take place after the blood is collected from the subject, or the tracer can be injected into the subject and allowed to equilibrate in the subject. A precise aliquot of the whole blood is counted to determine the quantity of tracer in whole blood, and a precise aliquot of plasma derived from the whole blood is counted to determine the quantity of tracer in the plasma. These counts are then used to derive the Hct using the equation
where Awb is the activity of the tracer in the whole blood sample, and Ap is the activity of the tracer in the plasma sample. In one embodiment, the method comprises
In one embodiment, the tracer is a radionuclide such as I-131, I-125, or Tc-99m bound to a plasma protein such as human serum albumin. In another preferred embodiment, the tracer is a radionuclide such as Tc-99m bound to red cells.
In one embodiment, the tracer is a fluorophore such as ICG, Fluorescein, or IRDye CW800 that is detectable directly in plasma, or a fluorophore bound to a plasma protein.
In one embodiment, quantitative collection vials are used to contain precise aliquots of plasma and blood, enabling POC use by eliminating the need for laboratory procedures such as precision pipetting.
In one embodiment, a plasma separation membrane is used to separate plasma from whole blood, enabling POC use by eliminating the need for laboratory procedures such as centrifugation. A plasma separation chamber has a plasma separation membrane blocking the egress, such that whole blood is introduced to the chamber at the ingress, and syringe pressure is sufficient to produce plasma at the egress.
In one embodiment, an automated POC blood volume analyzer calculates blood volume information for a subject determined by the injection of a plasma tracer and the application of the volume dilution method; samples are taken from the subject and placed in quantitative counting vials and counted at the bedside in a portable counter; plasma is extracted from one or more of the post-injection whole blood samples using a plasma separation membrane, such as a Polysulfone (PES) membrane.
The invention also provides a system for determining the Hematocrit (Hct) of a subject, consisting of a tracer that marks the plasma component of the blood, a concentration counter capable of measuring the activity of said tracer, containers for presenting samples to the concentration counter, and a plasma separator capable of producing a sample of plasma from a sample of whole blood, using the methods disclosed herein.
In one embodiment, the containers for presenting samples to the concentration counter are vials that are filled to a precise volume, Vwb and Vp for whole blood and plasma, using an ordinary syringe, wherein the activities are calculated as
and wherein the vials are vials of precise volume, comprising an ingress with a standard fitting for accepting fluid and a valve to prevent backflow or outflow of the fluid, and an egress incorporating a membrane which passes air but retains fluid.
In one embodiment, the plasma separator is a chamber with an input port for whole blood, a plasma separating membrane, and an output port that connects to the ingress of the vials.
The invention further provides a system for automatically analyzing blood of a living subject at the point of care (POC), comprising a concentration counter configured to analyze one or more samples, a user interface operatively connected to the concentration counter and configured for entry and display of information, one or more processors operatively coupled to a memory and configured to execute programmed instructions stored in the memory to carry out a method comprising the steps of:
The essential requirements for a quantitative blood collection vial are that it enable collection of a precise amount of blood directly from a subject; that the amount of blood is not limited to the quantity that can be collected by capillary action; that the collection process not require specialized skills beyond those possessed by a phlebotomist; and that the collected sample can immediately be counted in a quantitative detector in the collection vial.
Gamma scintillation detectors have a geometry effect. When a sample is placed into a counting well, the sample is surrounded on nearly all sides by the detector crystal, with the unavoidable exception of the solid angle subtended by the well opening. The farther down the well, the more efficient the counting will be; in the extreme case, a sample placed at the very opening of the well will have approximately half the counting efficiency, ignoring effects of absorbance by the well liner. Therefore, it is desirable to concentrate as much of the sample at the bottom of the well (i.e. at the bottom of the vial). Several embodiments are presented that achieve this objective.
A kit is provided for performance of an indicator dilution measurement, consisting of a plurality of labelled dimensionally identical vials as disclosed herein provided together in a suitable package. The kit also includes a radioactive tracer in a ready-to-inject container and a standard with a known dilution of said tracer in a vial that has a known ratio of volume to the vials.
A system is provided for performing an indicator dilution measurement using said kit to determine an unknown volume whereby an injectable tracer is injected into an unknown volume. After a short interval (to ensure mixing has occurred), a sample is collected from the subject into an empty collection volume of identical dimensions. By counting the standard vial and the patient vial, the patient volume can be computed using the simple ratio:
One skilled in the art will recognize how background measurements (from patient and room) can be accounted for by subtracting the relevant counts, and how multiple time samples can be taken to improve the accuracy of the measurement and account for loss of the tracer from the circulation over time.
This application claims the benefit of U.S. Provisional Patent Application No. 63/602,727, filed on Nov. 27, 2023, the contents of which are herein incorporated by reference in their entirety into the present application.
Number | Date | Country | |
---|---|---|---|
63602727 | Nov 2023 | US |